Tesamorelin vs Tirzepatide: What the Research Shows
Tesamorelin and Tirzepatide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Tesamorelin if…
- you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[7]
- you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[16]
Consider Tirzepatide if…
- you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[18]
- you want large randomized weight-loss data (the SURMOUNT program): Mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) with tirzepatide versus -3.1% with placebo.[17]
- you are tested in sport and want to avoid a WADA-prohibited substance: WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin (check tirzepatide's own status separately)[4]
Spec comparison
Showing 10 of 13 fields where the two differ. PCAC vote, Jul 2026, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.
| Field | Tesamorelin | Tirzepatide |
|---|---|---|
| Class | GHRH analog | GLP-1 / GIP dual agonist |
| Also called | tesa, Egrifta | tirz, tirze, Mounjaro, Zepbound |
| Category | Growth hormone | GLP-1 & metabolic |
| FDA status | FDA approved (Egrifta) | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | 12 human (11 randomized or controlled) of 16 summarised | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Tesamorelin and Tirzepatide together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Visceral fat in HIV versus weight loss in obesity
The Egrifta WR label states that the drug has a weight neutral effect and is not indicated for weight loss management.[7]
In a tirzepatide trial, weight change was -20.9% with 15-mg doses against -3.1% with placebo.[17]
Tesamorelin lowered visceral fat in an HIV trial: 15.2% down on tesamorelin, 5.0% up on placebo.[16]
In obese subjects with relative reductions in GH, tesamorelin selectively reduced visceral fat without significant effects on subcutaneous adipose tissue.[19]
A meta-analysis of tesamorelin in HIV observed growth hormone-related adverse effects and higher discontinuation rates; the discontinuation difference did not reach statistical significance (p = 0.06).[20]
Schedule and labelled use
The Egrifta WR label's recommended dosage is 1.28 mg subcutaneously once daily.[7]
The Zepbound label says to increase the dosage in 2.5 mg increments after at least 4 weeks until the recommended maintenance dosage is achieved.[18]
The Zepbound label's indication is to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related comorbid condition.[18]
The tesamorelin label lists glucose intolerance or diabetes mellitus among conditions that may develop with Egrifta WR use.[7]
Tesamorelin is a named example in WADA's GHRH-analogue entry.[4]
Common questions
Is tesamorelin or tirzepatide better for belly fat?
Egrifta WR's label is explicit that it is not indicated for weight loss management.[7]
Can you take tesamorelin and tirzepatide together?
No study in the cached results combines them. The tesamorelin label says glucose intolerance or diabetes mellitus may develop with use.[7]
Tesamorelin vs Mounjaro: what is the difference?
Tesamorelin (Egrifta WR) is indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy.[7]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 6Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 7EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 8The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 9Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 10The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 11These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 12Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 13Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 14Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 15PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 17Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 18ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 19Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
- 20Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026
Found an error? Report a correction.